Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Macugen for serous pigment epithelial detachment in exudative age-related macular degeneration
2006-006312-30Phase 4Completed
- Sponsor
- Semmelweis University Department of Ophthalmology
- Start
- Jan 2007
- Modality
- Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of pegaptanib sodium in exudative macular degeneration, age-related macular degeneration (AMD) and serous pigment epithelial detachment (SRPED), sponsored by Semmelweis University Department of Ophthalmology. Primary endpoint: proportion of patients losing <15 letters of distance visual acuity at 54 weeks. Started Jan 2007; status: completed.
02
Drugs
pegaptanib sodium
03
Conditions
exudative macular degenerationage-related macular degeneration (AMD)serous pigment epithelial detachment (SRPED)
Beyond the preview
Go deeper on 2006-006312-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-006312-30.